Jun. 28 at 3:00 PM
$MNKD $UTHR $AMPH
If Afrezza pediatrics, Clofazimine (CIS), and Nintedanib DPI all get FDA approved, whether Mannkind sells alone or with p'ships, MNKD becomes a
$50+ stock.
APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [Before EOY 2028]:
+
$10 -- pediatric Afrezza
+
$3 -- gestational Afrezza
+
$7 -- Clofazimine nebulized (CIS)
+
$3 -- Clofazimine DPI
+
$12 -- Nintedanib DPI
+
$4 -- TYVASO for IPF
+
$6 -- TYVASO for PPF
@jerchess
